Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Eran Rotem CPA

Market Cap

80.65 Million USD

Sector

Healthcare

Website

https://www.collplant.com

Description

CollPlant Biotechnologies Ltd.

Read More

Overview

Value

6

Growth

42

Health

65

Management

61

Analyst Opinion

60

Total

42

All Scores Out Of 100

Best Features

  • Has a low level of debt
  • Low risk of bankruptcy
  • Has strong financial health
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Earnings have declined recently
  • Income is not covering expenditure and investment
  • There is a history of diluting shareholders
  • No margin of safety at their current market price
  • Disliked by Twitter users
  • 0

Market Peers

CLGN

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

-58.43%

Revenue Growth (5 Year Average)

24.86%

Ratings Consensus

Neutral

Share Buybacks

-44.75%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

6

  • Estimated intrinsic-value of 3.00 USD is lower than current price ( 7.21 USD)
  • Free-cashflow-yeild of -18.39% is worse than the market average (4.7%)
  • Margin-of-safety of -58.43% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 3 USD

Current Price: 7.2 USD

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-18.39%

PE/Earnings Growth

N/A

Price/Book

2.25x

Growth

Growth Score

42

  • 5 Year Average Revenue growth of 24.86% is higher than the market average (10.97%)
  • Revenue growth has slowed this year
  • 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
  • Earnings growth has slowed this year
  • 5 Year Average Free Cashflow growth of N/A is lower than the market average (12.35%)
  • Free Cashflow growth has slowed this year

Revenue Growth

24.86%

Earnings Growth

N/A

Cashflow Growth

N/A

Health

Health Score

65

  • Low risk of bankruptcy
  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Debt repayments do not significantly impact cashflow
  • Cashflow is negative

Altman Z Score

7.53

Piostroski Score

3.00

Debt/Equity

0.08x

Current Assets/Liabilities

14.96x

Free Cashflow/Total Debt

0.25x

Debt/Capital

0.08x

Management

Management Score

61

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of 3.62% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of 0.50% is lower than the market average (15%)

Average Buybacks/Dilution

-44.75%

Recent Buybacks/Dilution

12.21%

5 Year Price Volitility

32.80%

Return On Assets

0.44%

Return On Capital Employed

3.62%

Return On Equity

0.50%

Return On Free Cashflow

-4.50%

Return On Investments

N/A

Social Sentiment

Social Sentiment Score

20

Twitter Sentiment

N/A

Stocktwits Sentiment

39.00

Analysts

Analyst Opinion

60

  • Ratings consensus is Neutral

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

CollPlant Biotechnologies Ltd.

Currency

USD

Beta

0.689222

Vol Avg

30642

Ceo

Mr. Eran Rotem CPA

Cik

0001631487

Cusip

19516R107

Exchange

NASDAQ Global Market

Full Time Employees

66

Industry

Biotechnology

Sector

Healthcare

Ipo Date

1993-09-01

Address

4 Oppenheimer Street, P.O. Box 4132

City

Rehovot

State

Country

IL

Zip

7670104

Phone

972732325600

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies